Scarica l'app Stockscreener
9.91
6.51%
-0.69
Pre-mercato:
9.98
0.07
+0.71%
Precedente Chiudi:
$10.60
Aprire:
$10.77
Volume 24 ore:
2.08M
Relative Volume:
1.95
Capitalizzazione di mercato:
$535.90M
Reddito:
$15.84M
Utile/perdita netta:
$-308.48M
Rapporto P/E:
-1.5293
EPS:
-6.48
Flusso di cassa netto:
$-153.08M
1 W Prestazione:
-30.99%
1M Prestazione:
-24.64%
6M Prestazione:
+114.50%
1 anno Prestazione:
+90.21%
Intervallo 1D:
$9.84
$11.43
Intervallo di 1 settimana:
$9.38
$14.57
Portata 52W:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
9.91 | 535.90M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval - insights.citeline.com
Learn to Evaluate (QURE) using the Charts - Stock Traders Daily
Stock Watch: Are Gene Therapy Prices Too High For Success? - insights.citeline.com
(QURE) Trading Report - Stock Traders Daily
uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World
Oppenheimer & Co. Inc. Buys New Stake in uniQure (NASDAQ:QURE) - Defense World
FY2025 Earnings Estimate for uniQure Issued By HC Wainwright - Defense World
uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - Defense World
uniQure CFO Christian Klemt sells $107,407 in shares By Investing.com - Investing.com Australia
uniQure Reports 2024 Financial Results and Progress - TipRanks
uniQure’s chief medical officer sells shares worth $13,891 - Investing.com India
uniQure CFO Christian Klemt sells $107,407 in shares - Investing.com India
uniQure’s chief medical officer sells shares worth $13,891 By Investing.com - Investing.com South Africa
uniQure CEO Matthew Kapusta sells shares worth $291,628 By Investing.com - Investing.com South Africa
uniQure chief legal officer sells shares for $72,812 By Investing.com - Investing.com South Africa
uniQure CEO Matthew Kapusta sells shares worth $291,628 - Investing.com
uniQure chief legal officer sells shares for $72,812 - Investing.com
uniQure (NASDAQ:QURE) Stock Price Down 7.3% Following Analyst Downgrade - Defense World
Wells Fargo & Company Cuts uniQure (NASDAQ:QURE) Price Target to $30.00 - Defense World
What is William Blair’s Forecast for uniQure Q1 Earnings? - Defense World
Don't Ignore The Insider Selling In uniQure - Simply Wall St
Q1 Earnings Estimate for uniQure Issued By William Blair - Defense World
uniQure Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 26,727 Shares of Stock - MarketBeat
uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta Sells 6,717 Shares - MarketBeat
uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 14,341 Shares - MarketBeat
uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 2,916 Shares - MarketBeat
uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Misses Expectations By $0.90 EPS - MarketBeat
uniQure (NASDAQ:QURE) Shares Down 9.5%Should You Sell? - MarketBeat
uniQure (NASDAQ:QURE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
uniQure (NASDAQ:QURE) Given Average Rating of “Buy” by Brokerages - Defense World
Uniqure NV earnings missed by $0.82, revenue fell short of estimates - Investing.com Australia
uniQure CEO Matthew Kapusta sells over $360,000 in stock By Investing.com - Investing.com South Africa
uniQure CEO Matthew Kapusta sells over $360,000 in stock - Investing.com India
uniQure CFO Christian Klemt sells shares worth over $186,000 By Investing.com - Investing.com South Africa
uniQure CFO Christian Klemt sells shares worth over $186,000 - Investing.com
Uniqure NV reports results for the quarter ended December 31Earnings Summary - TradingView
uniQure N.V. SEC 10-K Report - TradingView
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
uniQure Reports 2024 Financial Results and Company Progress - TradingView
uniQure N.V. Reports Progress with AMT-130 for Huntington’s Disease and Updates on Clinical Trials Across its Gene Therapy Pipeline - Nasdaq
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
uniQure N.V.: A Potential Huntington's Play - Seeking Alpha
uniQure (QURE) Expected to Announce Earnings on Wednesday - Defense World
(QURE) Technical Data - Stock Traders Daily
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
Pfizer nixes Roche-partnered hemophilia drug (PFE:NYSE) - Seeking Alpha
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66% - Yahoo Finance
24,749 Shares in uniQure (NASDAQ:QURE) Acquired by Palumbo Wealth Management LLC - MarketBeat
uniQure (NASDAQ:QURE) Stock Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):